Glioblastoma in the elderly: Making sense of the evidence

Neuro-Oncology Practice

Volumn 3, Issue 2, 2016, Pages 77-86

  Mason, Matthew ^a   Laperriere, Normand ^a   Wick, Wolfgang ^b   Reardon, David A ^c   Malmstrom, Annika ^d   Hovey, Elizabeth ^e   Weller, Michael ^f   Perry, James R ^g  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d LINKÖPING UNIVERSITY   (Sweden)

^e PRINCE OF WALES HOSPITAL   (Australia)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Chemotherapy; Elderly; Glioblastoma; Radiotherapy; Surgery

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

AGE; AGED; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER REHABILITATION; CANCER SURVIVAL; DRUG EFFICACY; GENE EXPRESSION; GENE MUTATION; GLIOBLASTOMA; HUMAN; HYPOFRACTIONATED RADIOTHERAPY; INCIDENCE; METHYLATION; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; TUMOR VOLUME;

EID: 84995669865     PISSN: 20542577     EISSN: 20542585     Source Type: Journal    
DOI: 10.1093/nop/npv027     Document Type: Article

References (56)

1. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41(2):67-76.
2. Ostrom QT, Gittleman H, Farah P, et al. CBTRUS statistical report:Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol. 2013;15(Suppl 2):ii1-ii56.
3. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109.
4. Batchelor TT, Betensky RA, Esposito JM, et al. Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res. 2004;10(1 Pt 1):228-233.
5. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110.
6. Lee Y, Scheck AC, Cloughesy TF, et al. Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics. 2008;1:52.
7. Wiestler B, Claus R, Hartlieb SA, et al. Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro Oncol. 2013;15(8):1017-1026.
8. Simpson JR, Horton J, Scott C, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys. 1993;26(2):239-244.
9. Kreth FW, Thon N, Simon M, et al. Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy. Ann Oncol. 2013;24(12):3117-3123.
10. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95(2):190-198.
11. Vuorinen V, Hinkka S, Farkkila M, Jaaskelainen J. Debulking or biopsy of malignant glioma in elderly people - a randomised study. Acta Neurochir (Wien). 2003;145(1):5-10.
12. Chaichana KL, Garzon-Muvdi T, Parker S, et al. Supratentorial glioblastoma multiforme: the role of surgical resection versus biopsy among older patients. Ann Surg Oncol. 2011;18(1):239-245.
13. Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012; 13(7):707-715.
14. Malmstrom A, Gronberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13(9):916-926.
15. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
16. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study:5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-466.
17. Laperriere N, Weller M, Stupp R, et al. Optimal management of elderly patients with glioblastoma. Cancer Treat Rev. 2013;39(4):350-357.
18. Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007;356(15):1527-1535.
19. Scott J, Tsai YY, Chinnaiyan P, Yu HH. Effectiveness of radiotherapy for elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys. 2011; 81(1):206-210.
20. Pedicini P, Fiorentino A, Simeon V, et al. Clinical radiobiology of glioblastoma multiforme: Estimation of tumor control probability from various radiotherapy fractionation schemes. Strahlenther Onkol. 2014;190(10):925-932.
21. Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004;22(9):1583-1588.
22. Baker SD, Wirth M, Statkevich P, et al. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res. 1999;5(2):309-317.
23. Weller M, Stupp R, Reifenberger G, et al. MGMTpromoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol. 2010;6(1):39-51.
24. Gerstner ER, Yip S,Wang DL, Louis DN, Iafrate AJ, Batchelor TT. Mgmt methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma. Neurology. 2009;73(18):1509-1510.
25. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003.
26. Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013;31(32):4085-4091.
27. Reifenberger G, Hentschel B, Felsberg J, et al. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer. 2012;131(6):1342-1350.
28. Perry JR, Callaghan CO, Ding K, et al. A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (NCIC CTG CE.6, EORTC 26062-22061, TROG 08.02). J Clin Oncol. 2012;30(suppl; abstr TPS2104).
29. Gallego Perez-Larraya J, Ducray F, Chinot O, et al. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. J Clin Oncol. 2011; 29(22):3050-3055.
30. Weller M, Van den Bent M, Hopkins K, et al. for the European Association for Neuro-Oncology (EANO) Task Force on Malignant Glioma. EANO Guideline on the Diagnosis and Treatment of Malignant Glioma. Lancet Oncol 2014;15:e395-e403.
31. Karayan-Tapon L, Quillien V, Guilhot J, et al. Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. J Neurooncol. 2010; 97(3):311-322.
32. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5):740-745.
33. Nghiemphu PL, Liu W, Lee Y, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology. 2009;72(14):1217-1222.
34. Lai A, Tran A, Nghiemphu PL, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011; 29(2):142-148.
35. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapytemozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709-722.
36. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699-708.
37. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205-216.
38. Chinot OL, Macdonald DR, Abrey LE, Zahlmann G, Kerloeguen Y, Cloughesy TF. Response assessment criteria for glioblastoma:practical adaptation and implementation in clinical trials of antiangiogenic therapy. Curr Neurol Neurosci Rep. 2013;13(5):347.
39. Sandmann T, Bourgon R, Garcia J, et al. Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide:Retrospective analysis of the AVAglio trial [published online ahead of print June 29, 2015]. J Clin Oncol. doi:10.1200/JCO.2015.61.5005.
40. Weiler M, Blaes J, Pusch S, et al. The mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proc Natl Acad Sci USA. 2014;111(1):409-414.
41. Dahlin CM, Kelley JM, Jackson VA, Temel JS. Early palliative care for lung cancer: improving quality of life and increasing survival. Int J Palliat Nurs. 2010;16(9):420-423.
42. Paszat L, Laperriere N, Groome P, Schulze K, MackillopW, Holowaty E. A population-based study of glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2001;51(1):100-107.
43. Rosenthal MA, Drummond KJ, Dally M, et al. Management of glioma in Victoria (1998-2000): retrospective cohort study. Med J Aust. 2006;184(6):270-273.
44. Chang SM, Parney IF, Huang W, et al. Patterns of care for adults with newly diagnosed malignant glioma. JAMA. 2005;293(5):557-564.
45. Kita D, Ciernik IF, Vaccarella S, et al. Age as a predictive factor in glioblastomas: population-based study. Neuroepidemiology. 2009; 33(1):17-22.
46. Iwamoto FM, Reiner AS, Panageas KS, Elkin EB, Abrey LE. Patterns of care in elderly glioblastoma patients. Ann Neurol. 2008;64(6):628-634.
47. Coate L, McNamara MG, Lwin Z, et al. Glioblastoma treatment in the elderly in the temozolomide therapy era. Can J Neurol Sci. 2014; 41(3):357-362.
48. Tsang DS, Khan L, Perry JR, et al. Survival outcomes in elderly patients with glioblastoma. Clin Oncol (R Coll Radiol). 2015;27(3):176-183.
49. Geler-Kulcu D, Gulsen G, Buyukbaba E, Ozkan D. Functional recovery of patients with brain tumor or acute stroke after rehabilitation: a comparative study. J Clin Neurosci. 2009;16(1):74-78.
50. Huang ME, Cifu DX, Keyser-Marcus L. Functional outcome after brain tumor and acute stroke: a comparative analysis. Arch Phys Med Rehabil. 1998;79(11):1386-1390.
51. Huang ME, Cifu DX, Keyser-Marcus L. Functional outcomes in patients with brain tumor after inpatient rehabilitation: comparisonwith traumatic brain injury. Am J Phys Med Rehabil. 2000;79(4):327-335.
52. O'Dell MW, Barr K, Spanier D, Warnick RE. Functional outcome of inpatient rehabilitation in persons with brain tumors. Arch Phys Med Rehabil. 1998;79(12):1530-1534.
53. Australian Cancer Network Adult Brain Tumour Guidelines Working Party. Clinical Practice Guidelines for the Management of Adult Gliomas: Astrocytomas and Oligodendrogliomas. Sydney, Australia:Cancer Council Australia, Australian Cancer Network and Clinical Oncological Society of Australia Inc.; 2009.
54. Schubart JR, Kinzie MB, Farace E. Caring for the brain tumor patient:family caregiver burden and unmet needs. Neuro Oncol. 2008;10(1):61-72.
55. Janda M, Steginga S, Langbecker D, Dunn J,Walker D, Eakin E. Quality of life among patients with a brain tumor and their carers. J Psychosom Res. 2007;63(6):617-623.
56. Wick W, Weller M, van den Bent M, et al. MGMT testing in neurooncology - A paradigm for prospects and challenges of biomarker-based treatment decisions. Nat Rev Neurol. 2014;10:372-385.